The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 14, 2023

Filed:

Mar. 09, 2021
Applicant:

Amorsa Therapeutics, Inc., Littleton, MA (US);

Inventors:

Alex Nivorozhkin, West Roxbury, MA (US);

Nelson Landrau, Marlborough, MA (US);

Assignee:

Amorsa Therapeutics, Inc., Littleton, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 225/20 (2006.01); C07B 59/00 (2006.01); A61K 45/06 (2006.01); A61K 9/20 (2006.01); A61K 31/135 (2006.01);
U.S. Cl.
CPC ...
C07C 225/20 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 31/135 (2013.01); A61K 45/06 (2013.01); C07B 59/001 (2013.01); C07B 2200/05 (2013.01); C07C 2601/14 (2017.05);
Abstract

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.


Find Patent Forward Citations

Loading…